Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 54

1.

Understanding the conservation patterns and molecular phylogenetics of human death receptors family through computational biology.

Tomar J, Chakraborty C, Doss CG, Gera VK.

3 Biotech. 2014 Apr;4(2):177-187. doi: 10.1007/s13205-013-0141-5. Epub 2013 May 25.

2.

Death Receptor 3 Promotes Chemokine-Directed Leukocyte Recruitment in Acute Resolving Inflammation and Is Essential for Pathological Development of Mesothelial Fibrosis in Chronic Disease.

Perks WV, Singh RK, Jones GW, Twohig JP, Williams AS, Humphreys IR, Taylor PR, Jones SA, Wang EC.

Am J Pathol. 2016 Nov;186(11):2813-2823. doi: 10.1016/j.ajpath.2016.07.021. Epub 2016 Sep 21.

3.

Cytokine and anti-cytokine therapies in prevention or treatment of fibrosis in IBD.

Jacob N, Targan SR, Shih DQ.

United European Gastroenterol J. 2016 Aug;4(4):531-40. doi: 10.1177/2050640616649356. Epub 2016 May 10. Review.

4.

Characterization of death receptor 3-dependent aortic changes during inflammatory arthritis.

Williams JO, Wang EC, Lang D, Williams AS.

Pharmacol Res Perspect. 2016 Jun 10;4(4):e00240. eCollection 2016 Aug.

5.

A Novel Role for TL1A/DR3 in Protection against Intestinal Injury and Infection.

Jia LG, Bamias G, Arseneau KO, Burkly LC, Wang EC, Gruszka D, Pizarro TT, Cominelli F.

J Immunol. 2016 Jul 1;197(1):377-86. doi: 10.4049/jimmunol.1502466. Epub 2016 May 27.

PMID:
27233964
6.

Expression and function of the TL1A/DR3 axis in chronic lymphocytic leukemia.

Cavallini C, Lovato O, Bertolaso A, Zoratti E, Malpeli G, Mimiola E, Tinelli M, Aprili F, Tecchio C, Perbellini O, Scarpa A, Zamò A, Cassatella MA, Pizzolo G, Scupoli MT.

Oncotarget. 2015 Oct 13;6(31):32061-74. doi: 10.18632/oncotarget.5201.

7.

The TNF-family cytokine TL1A: from lymphocyte costimulator to disease co-conspirator.

Richard AC, Ferdinand JR, Meylan F, Hayes ET, Gabay O, Siegel RM.

J Leukoc Biol. 2015 Sep;98(3):333-45. doi: 10.1189/jlb.3RI0315-095R. Epub 2015 Jul 17. Review.

8.

The TNF-family ligand TL1A and its receptor DR3 promote T cell-mediated allergic immunopathology by enhancing differentiation and pathogenicity of IL-9-producing T cells.

Richard AC, Tan C, Hawley ET, Gomez-Rodriguez J, Goswami R, Yang XP, Cruz AC, Penumetcha P, Hayes ET, Pelletier M, Gabay O, Walsh M, Ferdinand JR, Keane-Myers A, Choi Y, O'Shea JJ, Al-Shamkhani A, Kaplan MH, Gery I, Siegel RM, Meylan F.

J Immunol. 2015 Apr 15;194(8):3567-82. doi: 10.4049/jimmunol.1401220. Epub 2015 Mar 18. Erratum in: J Immunol. 2015 Dec 15;195(12):5839-40.

9.

TL1-A can engage death receptor-3 and activate NF-kappa B in endothelial cells.

Wang J, Al-Lamki RS, Zhu X, Liu H, Pober JS, Bradley JR.

BMC Nephrol. 2014 Nov 16;15:178. doi: 10.1186/1471-2369-15-178.

10.

The role of death receptor 3 in the biological behavior of hepatocellular carcinoma cells.

Zhang YC, Guo LQ, Chen X, Wang GN, Ni R, Wang MC, Wei FX.

Mol Med Rep. 2015 Feb;11(2):797-804. doi: 10.3892/mmr.2014.2858. Epub 2014 Nov 4.

11.

Regulation of early cartilage destruction in inflammatory arthritis by death receptor 3.

Wang EC, Newton Z, Hayward OA, Clark SR, Collins F, Perks WV, Singh RK, Twohig JP, Williams AS.

Arthritis Rheumatol. 2014 Oct;66(10):2762-72. doi: 10.1002/art.38770.

12.

The role of TL1A and DR3 in autoimmune and inflammatory diseases.

Aiba Y, Nakamura M.

Mediators Inflamm. 2013;2013:258164. doi: 10.1155/2013/258164. Epub 2013 Dec 21. Review.

13.

Membrane trafficking of death receptors: implications on signalling.

Schneider-Brachert W, Heigl U, Ehrenschwender M.

Int J Mol Sci. 2013 Jul 11;14(7):14475-503. doi: 10.3390/ijms140714475. Review.

14.

Death receptor-ligand systems in cancer, cell death, and inflammation.

Walczak H.

Cold Spring Harb Perspect Biol. 2013 May 1;5(5):a008698. doi: 10.1101/cshperspect.a008698. Review.

15.

The TNF-family cytokine TL1A inhibits proliferation of human activated B cells.

Cavallini C, Lovato O, Bertolaso A, Pacelli L, Zoratti E, Zanolin E, Krampera M, Zamò A, Tecchio C, Cassatella MA, Pizzolo G, Scupoli MT.

PLoS One. 2013;8(4):e60136. doi: 10.1371/journal.pone.0060136. Epub 2013 Apr 2.

17.

Aberrant expression and function of death receptor-3 and death decoy receptor-3 in human cancer.

Ge Z, Sanders AJ, Ye L, Jiang WG.

Exp Ther Med. 2011 Mar;2(2):167-172. Epub 2011 Jan 20.

18.

TNFSF15 Modulates Neovascularization and Inflammation.

Zhang Z, Li LY.

Cancer Microenviron. 2012 Dec;5(3):237-47. doi: 10.1007/s12307-012-0117-8. Epub 2012 Jul 26.

19.

On death receptor 3 and its ligands….

Wang EC.

Immunology. 2012 Sep;137(1):114-6. doi: 10.1111/j.1365-2567.2012.03606.x. No abstract available.

20.

The death receptor 3/TL1A pathway is essential for efficient development of antiviral CD4⁺ and CD8⁺ T-cell immunity.

Twohig JP, Marsden M, Cuff SM, Ferdinand JR, Gallimore AM, Perks WV, Al-Shamkhani A, Humphreys IR, Wang EC.

FASEB J. 2012 Aug;26(8):3575-86. doi: 10.1096/fj.11-200618. Epub 2012 May 16.

Supplemental Content

Support Center